Current clinical trials with authentic recombinant human growth hormone in Japan.
Daily injections of methionine-free, recombinant hGH (rhGH), 8 IU, were administered in six healthy volunteers. Non-esterified fatty acid levels increased significantly from 0.45 +/- 0.06 to 1.08 +/- 0.05 mEq/litre (mean +/- SEM) at 4 hours after the first injection of rhGH (p less than 0.001). Plasma IGF-1 levels increased significantly at 24 hours after each of the four daily injections of rhGH (basal, 0.80 +/- 0.06 units/ml; 24 hours, 1.72 +/- 0.21 units/ml; 48 hours, 3.22 +/- 0.42 units/ml; 72 hours, 3.17 +/- 0.49 units/ml; 96 hours, 3.63 +/- 0.32 units/ml; p less than 0.001). Eleven patients with hGH deficiency were treated with rhGH, 0.5 IU/kg/week for 3 months. Their heights increased by between 1.1 cm and 4.1 cm during the 3 months of treatment, which was calculated to be equivalent to 4.4-16.4 cm/year, with a mean height velocity of 8.6 +/- 1.1 cm/year. Anti-hGH antibody was observed in one patient treated with rhGH and had a titre of 10.
Takano
K
K
Shizume
K
K
D000293:Adolescent; D000917:Antibody Formation; D002648:Child; D002986:Clinical Trials as Topic; D004393:Dwarfism, Pituitary / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006128:Growth / Q000187:drug effects; D013006:Growth Hormone / Q000172:deficiency / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000097:blood; D008297:Male; D011994:Recombinant Proteins / Q000009:adverse effects / Q000276:immunology / Q000494:pharmacology
D011994:Recombinant Proteins; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone